Melanoma metastasis

Melanoma metastasis is the advanced biological process by which malignant melanoma cells spread from the primary cutaneous tumor to distant sites such as the lungs, brain, liver, and bones (National Cancer Institute, 2023). This progression involves a complex multi-step cascade including local tissue invasion, intravasation into blood or lymphatic vessels, survival in the circulatory system, and eventual colonization of distant organs (Fidler, 2003). It is not a single molecular target but rather a systemic disease state driven by genetic alterations—most frequently mutations in the BRAF, NRAS, and KIT genes—and characterized by significant metabolic reprogramming and immune evasion (Shain & Bastian, 2016). Modern therapeutic approaches do not target 'metastasis' directly as a discrete molecule but instead focus on inhibiting specific signaling drivers or utilizing immunotherapy to enable the patient's immune system to recognize and destroy metastatic lesions. While the development of targeted therapies and checkpoint inhibitors has significantly improved survival rates for patients with stage IV disease, clinical management remains challenged by the emergence of drug resistance and systemic toxicity (Luke et al., 2017).

Other names

Metastatic melanomaDisseminated melanomaStage IV melanomaSecondary melanoma

Because melanoma metastasis is a disease process rather than a single molecule, drugs used to treat it target various underlying mechanisms. Targeted therapies such as BRAF inhibitors (e.g., Vemurafenib) and MEK inhibitors (e.g., Trametinib) arrest the MAPK/ERK signaling pathway to inhibit hyper-proliferation (Luke et al., 2017). Immunotherapies, including PD-1 inhibitors (e.g., Nivolumab) and CTLA-4 inhibitors (e.g., Ipilimumab), work by blocking immune checkpoints that metastatic cells use to evade detection, thereby restoring the T-cell-mediated anti-tumor response (Robert et al., 2015).